Thông tin thuốc gốc
Chỉ định và Liều dùng
Adjuvant therapy for postmenopausal women with hormone receptor positive early breast cancer
Adult: Following 2-3 yr initial adjuvant tamoxifen treatment, 25 mg once daily for a total of 5 yr of combined sequential adjuvant hormonal therapy; or earlier if tumour relapse occurs.

Advanced breast cancer in postmenopausal women
Adult: 25 mg once daily continued until evident tumour progression.
Special Patient Group
Patients on strong CYP3A4 enzyme inducers: 50 mg once daily.
Cách dùng
Should be taken with food.
Chống chỉ định
Premenopausal women. Pregnancy and lactation.
Thận trọng
Patient w/ uncontrolled HTN, osteoporosis and its potential causes (e.g. vit D deficiency, hyperthyroidism, hyperparathyroidism). Hepatic and renal impairment.
Phản ứng phụ
Significant: Decrease in BMD.
Nervous: Headache, dizziness, depression, insomnia, anxiety, neuropathy, paraesthesia.
CV: HTN, peripheral oedema.
GI: Diarrhoea, nausea, abdominal pain, anorexia, constipation, vomiting.
Resp: Dyspnoea.
Musculoskeletal: Arthralgia, myalgia, carpal tunnel syndrome, osteoarthritis, osteoporosis.
Ophthalmologic: Visual disturbances.
Dermatologic: Hot flushes, alopecia, increased sweating, dermatitis, rash.
Others: Fatigue.
Thông tin tư vấn bệnh nhân
This drug may cause drowsiness, asthenia, and dizziness, if affected, do not drive or operate machinery.
Monitor 25-hydroxy vit D level and BMD prior to therapy; and LFT. Assess for new or unusual bone pain or swelling of face, lips, or throat.
Tương tác
Decreased plasma levels of exemestane when used w/ strong CYP3A4 enzyme inducers (e.g. phenytoin, carbamazepine, rifampicin). Antagonised effect w/ oestrogens.
Food Interaction
Increased bioavailability w/ food. Decreased therapeutic effect w/ St John’s wort.
Tác dụng
Description: Exemestane is an irreversible, selective aromatase inhibitor which acts as a false substrate for the enzyme and forms an intermediate that binds to its active site. This leads to inactivation or suicide inhibition, thus preventing the conversion of androgens to oestrogens in peripheral tissues. It lowers circulating oestrogens in postmenopausal women w/ breast cancers where growth is oestrogen-dependent.
Absorption: Rapidly absorbed from the GI tract. Time to peak plasma concentration: 1.2 hr.
Distribution: Extensively distributed into tissues; crosses the placenta. Plasma protein binding: 90%, primarily to albumin and α1-acid glycoprotein.
Metabolism: Metabolised via oxidation by CYP3A4 enzyme and via reduction by aldoketoreductase into inactive metabolites.
Excretion: Via urine (>1% as unchanged drug; 39-45% as metabolites); faeces (36-48%). Elimination half-life: Approx 24 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Exemestane, CID=60198, https://pubchem.ncbi.nlm.nih.gov/compound/Exemestane (accessed on Jan. 23, 2020)

Bảo quản
Store between 20-25°C. 
Phân loại MIMS
Phân loại ATC
L02BG06 - exemestane ; Belongs to the class of enzyme inhibitors. Used in treatment of neoplastic diseases.
Anon. Exemestane. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/03/2017.

Buckingham R (ed). Exemestane. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/03/2017.

Exemestane Tablet, Film Coated (West-Ward Pharmaceuticals Corp). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/03/2017.

Joint Formulary Committee. Exemestane. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/03/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Exemestane. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 01/03/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Exemestane từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Aromasin
  • Linkotax
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in